News & Updates

Treatment with apremilast appears safe and effective against mild to moderate plaque psoriasis, according to a recent study.

The combination of the anti-PD-1 monoclonal antibody sintilimab with the bevacizumab biosimilar IBI305 and pemetrexed and cisplatin chemotherapy improved progression-free survival (PFS) in patients with EGFR*-mutated (EGFRm) non-squamous non-small-cell lung cancer (NSCLC), according to interim analysis results of the phase III ORIENT-31 trial from China.

Patients with hyperlipidemia who take their statin medication as prescribed appear to do well, with treatment adherence conferring significant protection against the risk of ischaemic and haemorrhagic strokes, as reported in a study.

The DESKTOP* III trial has shown that patients whose ovarian cancer recurs have better overall survival (OS) following secondary cytoreductive surgery plus platinum-based chemotherapy compared with a platinum-based chemotherapy regimen alone.

The novel third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) aumolertinib appears to be effective in the treatment of patients with EGFR T790M-positive advanced nonsmall cell lung carcinoma (NSCLC) following progression on first- and second-generation EGFR TKI therapy, according to data from the phase II APOLLO Registrational Trial.

Most patients with traumatic brain injury receive delayed prophylaxis, with no association seen between incidence of venous thromboembolism (VTE) and prophylaxis regimen, suggests a study. However, a significant difference is observed in VTE incidence stratified by time to prophylaxis.